Literature DB >> 25395318

Novel and recurrent BRCA2 mutations in Italian breast/ovarian cancer families widen the ovarian cancer cluster region boundaries to exons 13 and 14.

Anna Coppa1, Amelia Buffone, Carlo Capalbo, Arianna Nicolussi, Sonia D'Inzeo, Francesca Belardinilli, Valeria Colicchia, Marialaura Petroni, Teresa Granato, Cecilia Midulla, Massimo Zani, Sergio Ferraro, Isabella Screpanti, Alberto Gulino, Giuseppe Giannini.   

Abstract

Hereditary breast and ovarian cancer are mainly linked to mutations in BRCA1 and BRCA2 genes which confer a similar cumulative risk of developing breast cancer. Importantly, while BRCA2 mutation carriers generally have a lower cumulative risk for ovarian cancer, mutations clustered in the central portion of BRCA2 are associated with a higher proportion of ovarian compared with breast cancer cases. The boundaries of this ovarian cancer cluster region (OCCR) have been tentatively defined within a 3.3 kb region of BRCA2 exon 11, and herein, we reassessed these boundaries using our series of Italian breast/ovarian cancer families. We used direct sequencing to investigate BRCA mutations in 367 breast/ovarian cancer families. We also studied the association between the location of the mutations and the ovarian cancer phenotype in our cohort of BRCA2-mutated families. We observed the novel c.7309_7309delA frameshift mutation and the c.7007G>A deleterious mutation in BRCA2 exons 14 and 13, respectively, in five independent Italian families characterized by a high proportion of ovarian cancer cases. Of note, a significantly higher proportion of ovarian versus breast cancer cases was associated not only with mutations in the previously defined OCCR (OR = 5.91; p = 0.004), but also with the exon 13-14 region (OR = 7.37; p = 0.001) in our BRCA2-mutated families. Our data provide initial evidence for a novel putative OCCR in BRCA2 exons 13-14.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25395318     DOI: 10.1007/s10549-014-3196-z

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  8 in total

1.  Design, synthesis, and characterization of BRC4 mutants based on the crystal structure of BRC4-RAD51(191-220).

Authors:  Dongxin Zhao; Kui Lu
Journal:  J Mol Model       Date:  2015-11-02       Impact factor: 1.810

2.  Optimizing the identification of risk-relevant mutations by multigene panel testing in selected hereditary breast/ovarian cancer families.

Authors:  Anna Coppa; Arianna Nicolussi; Sonia D'Inzeo; Carlo Capalbo; Francesca Belardinilli; Valeria Colicchia; Marialaura Petroni; Massimo Zani; Sergio Ferraro; Christian Rinaldi; Amelia Buffone; Armando Bartolazzi; Isabella Screpanti; Laura Ottini; Giuseppe Giannini
Journal:  Cancer Med       Date:  2017-12-22       Impact factor: 4.452

3.  Next-generation sequencing of BRCA1 and BRCA2 genes for rapid detection of germline mutations in hereditary breast/ovarian cancer.

Authors:  Arianna Nicolussi; Francesca Belardinilli; Yasaman Mahdavian; Valeria Colicchia; Sonia D'Inzeo; Marialaura Petroni; Massimo Zani; Sergio Ferraro; Virginia Valentini; Laura Ottini; Giuseppe Giannini; Carlo Capalbo; Anna Coppa
Journal:  PeerJ       Date:  2019-04-22       Impact factor: 2.984

Review 4.  Multi gene panel testing for hereditary breast cancer - is it ready to be used?

Authors:  Andreea Catana; Adina Patricia Apostu; Razvan-Geo Antemie
Journal:  Med Pharm Rep       Date:  2019-07-31

5.  Identification of novel BRCA1 large genomic rearrangements by a computational algorithm of amplicon-based Next-Generation Sequencing data.

Authors:  Arianna Nicolussi; Francesca Belardinilli; Valentina Silvestri; Yasaman Mahdavian; Virginia Valentini; Sonia D'Inzeo; Marialaura Petroni; Massimo Zani; Sergio Ferraro; Stefano Di Giulio; Francesca Fabretti; Beatrice Fratini; Angela Gradilone; Laura Ottini; Giuseppe Giannini; Anna Coppa; Carlo Capalbo
Journal:  PeerJ       Date:  2019-11-15       Impact factor: 2.984

6.  Germline Testing in a Cohort of Patients at High Risk of Hereditary Cancer Predisposition Syndromes: First Two-Year Results from South Italy.

Authors:  Francesco Paduano; Emma Colao; Fernanda Fabiani; Valentina Rocca; Francesca Dinatolo; Adele Dattola; Lucia D'Antona; Rosario Amato; Francesco Trapasso; Francesco Baudi; Nicola Perrotti; Rodolfo Iuliano
Journal:  Genes (Basel)       Date:  2022-07-21       Impact factor: 4.141

7.  A novel BRCA2 splice variant identified in a young woman.

Authors:  Arianna Nicolussi; Francesca Belardinilli; Laura Ottini; Marialaura Petroni; Carlo Capalbo; Giuseppe Giannini; Anna Coppa
Journal:  Mol Genet Genomic Med       Date:  2020-11-07       Impact factor: 2.183

8.  Beyond BRCA1/2: Homologous Recombination Repair Genetic Profile in a Large Cohort of Apulian Ovarian Cancers.

Authors:  Antonella Turchiano; Daria Carmela Loconte; Rosalba De Nola; Francesca Arezzo; Giulia Chiarello; Antonino Pantaleo; Matteo Iacoviello; Rosanna Bagnulo; Annunziata De Luisi; Sonia Perrelli; Stefania Martino; Carlotta Ranieri; Antonella Garganese; Alessandro Stella; Cinzia Forleo; Vera Loizzi; Marco Marinaccio; Ettore Cicinelli; Gennaro Cormio; Nicoletta Resta
Journal:  Cancers (Basel)       Date:  2022-01-12       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.